Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Chuan Gu, Jian Feng(National University of Defense Technology), Jiuwei Cui(Jilin University), Gongyan Chen(Harbin Medical University), Ying Cheng(Jilin Province Tumor Hospital), Xiaodong Zhang(Shanghai Jiao Tong University), Aimin Zang, Lin Wu(Materials Systems (United States)), Yong Jiang(The First People's Hospital of Changzhou), Yuping Li(Guangdong Province Women and Children Hospital), Xiang Wang(Central South University), Chunling Liu(Guangdong Academy of Medical Sciences), Shucai Zhang(Northeastern University), Hui Zhao(Dalian Medical University), Jiwei Liu(Mongolian University of Science and Technology), Shuyang Zhu(Xuzhou Medical College), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Fei Liu(Cangzhou Central Hospital), Nong Yang(Central South University), Yanrong Hao(The People's Hospital of Guangxi Zhuang Autonomous Region)
Cited by 235
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k